| FORM  | 4      | UNITED STAT  | ES SECURITIES AND EXCHANGE COM   | MISSION  |                    |                         |  |  |  |  |
|---|--------|--|--|--|--------------------|-------------------------|--|--|--|--|
|   |        |  | Washington, D.C. 20549   | OMB APPROVAL   |                    |                         |  |  |  |  |
| Check this box if no lo<br>Section 16. Form 4 or<br>obligations may contin<br>Instruction 1(b). | ERSHIP | OMB Number: 3235-0287<br>Estimated average burden<br>hours per response: 0.5 |  |  |                    |                         |  |  |  |  |
| 1. Name and Address of<br><u>Vuori Kristiina N</u>  |        | 1*   | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br>Bionano Genomics, Inc. [BNGO]  | 5. Relationship of F<br>(Check all applicat                    | ,                  | to Issuer<br>0% Owner   |  |  |  |  |
| (Last) (Fi  | irst)  | (Middle)   | 3. Date of Earliest Transaction (Month/Day/Year)<br>06/18/2024   | Officer (g<br>below)   |                    | other (specify<br>elow) |  |  |  |  |
| C/O BIONANO GENOMICS, INC.<br>9540 TOWNE CENTRE DRIVE, SUITE 100                                |        |  | 4. If Amendment, Date of Original Filed (Month/Day/Year)   | 6. Individual or Joint/Group Filing (Check Applicable<br>Line) |                    |                         |  |  |  |  |
| (Street)<br>SAN DIEGO C   | Ą      | 92121  |  | Form filed<br>Person   | l by More than One | Reporting               |  |  |  |  |
|   |        |  | Rule 10b5-1(c) Transaction Indication  |  |                    |                         |  |  |  |  |
| (City) (Si  | tate)  | (Zip)  | Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. |  |                    |                         |  |  |  |  |
|   | Ta     | ble I - Non-Deriva   | ative Securities Acquired, Disposed of, or Benefic   | cially Owned   |                    |                         |  |  |  |  |

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 3.<br>Transa<br>Code (<br>8) | oction | 4. Securities Acquired (A) or<br>Disposed Of (D) (Instr. 3, 4 and<br>5) |               |       | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---------------------------------|--|---|------------------------------|--------|---|---------------|-------|---|---|---|
|                                 |  |   | Code                         | v      | Amount  | (A) or<br>(D) | Price | Transaction(s)<br>(Instr. 3 and 4)  |   | (   |

|   | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned   (e.g., puts, calls, warrants, options, convertible securities) |  |   |                              |   |        |     |  |                    |   |  |   |  |  |  |
|---|--|--|---|------------------------------|---|--------|-----|--|--------------------|---|--|---|--|--|--|
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security  | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transa<br>Code (<br>8) |   | of     |     | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount<br>of Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |  | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number of<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s)<br>(Instr. 4) | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|   |  |  |   | Code                         | v | (A)    | (D) | Date<br>Exercisable  | Expiration<br>Date | Title   | Amount<br>or<br>Number<br>of<br>Shares |   |  |  |  |
| Stock<br>Option<br>(Right to<br>Buy)                | <b>\$</b> 0.7752   | 06/18/2024                                 |   | A                            |   | 30,000 |     | (1)  | 06/18/2034         | Common<br>Stock   | 30,000                                 | \$0   | 30,000   | D  |  |

## Explanation of Responses:

1. The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan).

## Remarks:

SEC Form 4

## /s/ R. Erik Holmlin, Attorneyin-Fact 06/20/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.